Alzheimer's Foundation of America
Select text size: a | a | a
 

Clinical Trials

Find a Trial

To find a trial, please view the list below. Also visit www.clinicaltrials.gov.

Search by State:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
MARYLAND

Location: Annapolis
Anne Arundeel Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Elizabeth F. Egan
443-481-5811
eegan@aahs.org

Back to Top

Location: Baltimore
Harbor Hospital

Trial Title and Description:

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects with Mild to Moderate Alzheimer's Disease

Enrollment Status: Recruiting

Study Dates: Start April 2014

Condition: Alzheimer's disease
Age Eligibility: 55-85
Gender Eligibility: Both
Enrollment Goal: 121
Clinical Identifier: NCT02036645
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Medimmune

Contact Information:
Ruby Widerman
1.800.797.2448
study.baltimore@parexel.com
www.parexel.com/baltimore

Back to Top

Location: Baltimore
John Hopkins Hospital

Trial Title and Description: Depression in Alzheimer's Disease-

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication Sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

Enrollment Status: Recruiting

Study Dates: Start: July 2004

Condition: Alzheimer's disease, Depression
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2, 3
Study Type: Interventional

Sponsor: National Institute of Mental Health (NIMH)

Contact Information:
Ann Morrison
410-614-4605
amorris7@jhmi.edu

Back to Top

Location: Baltimore
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Paul Rosenburg
877-379-3718

Back to Top

Location: Glen Burnie
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Lawrence Adler
877-379-3718

Back to Top

Location: Oxon Hill
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stephen Ong
877-379-3718

Back to Top

Location: Rockville
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
David Denicoff
877-379-3718

Back to Top

Location: Call for details

Trial Title and Description: Brain Study of Patients with Frontal Lobe Dementia and Parkinsonian Disorders-

National Institute of Neurological Disorders and Stroke proposes to continue its cross-sectional and longitudinal studies of cerebral metabolism in frontal lob dementias and atypical basal ganglia disorders. These studies include repeated assessments of neuropsychological and brain anatomical and metabolic function in subjects with these important and possibly related brain disorders.

Enrollment Status: Recruiting

Study Dates: Start: January 1981

Condition: Alzheimer's disease, Dementia, Down's syndrome
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 675
Clinical Identifier: NCT00001178
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Contact Information:
Patient Recruitment and Public Liaison Office
800-411-1222

Back to Top

Location: Call for details

Trial Title and Description: MRI of Alzheimer's Disease: Imaging Amyloid Plaques in Persons With and Without Memory Problems-

This study will investigate the possibility of detecting early signs of Alzheimer's disease using magnetic resonance imaging (MRI). If plaques can be imaged by MRI, the procedure could be used in clinical trials and may also help in the clinical diagnosis of patients.

Enrollment Status: Recruiting

Study Dates: Start: December 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 40
Clinical Identifier: NCT00413621
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Contact Information:
Andrea Nelson
anelson18@jhmi.edu

Back to Top

Location: Call for details

Trial Title and Description: PET Scanning [11C] MeS-IMPY to Measure Amyloid in Brain-

This study will use positron emission tomography (PET) to measure a protein called amyloid in the brains of healthy volunteers and people with Alzheimer's disease. The tracer used in this study is a research drug called [11C] MeS-IMPY.

Enrollment Status: Recruiting

Study Dates: Start: December 2006

Condition: Alzheimer's disease, Neurodegenerative disease, Dementia
Age Eligibility: Healthy subjects: 18-80 Alzheimer's diseases: 50-80
Gender Eligibility: Both
Enrollment Goal: 15
Clinical Identifier: NCT00407576
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute of Mental Health

Contact Information:
Patient Recruitment and Public Liaison Office
800-411-1222

Back to Top

MASSACHUSETTS

Location: Boston

Trial Title and Description: Safety and Efficacy Study Evaluating Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease

The purpose of this study is to determine if Bapineuzumab is safe and effective in patients with mild to moderate Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates:  Start: February 2012  
Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 50 to 88 at time of enrollment
Gender Eligibility: Both
Enrollment Goal: 1800 (540 in the US)
Clinical Identifier: NCT00667810
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Wyeth, a Pfizer Company
Collaborator: Pfizer

Contact Information:
Martha Vander Vliet, RN
617-525-8383

Back to Top

Location: Burlington
Lahey Clinic, Inc.

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Junius Beebe
781-744-5601
Junius.O.Beebe@lahey.org

Back to Top

Location: Pittsffield
Berkshire Hematologgy Oncology/ Bershire Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Gloria F. Gero
413-496-8205

Back to Top

Location: Alzheimers Disease Center, Quincy Medical Center, Quincy, MA

Trial Title and Description: (title) A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5mg, 2mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy.

(description) The purpose of this study is to test the safety and effectiveness of an investigational drug SAR110894D compared to placebo in treating Alzheimer's disease symptoms in subjects who take donepezil. SAR110894D will be evaluated by performing tests that check attention, concentration, language, memory, reasoning and movement skills. Patient should have an MMSE between 15-25, inclusive and be on donepezil (Aricept) only.

Enrollment Status: Recruiting

Study Dates: Start: January 2011 Expected Completion: TBD

Condition: Alzheimer’s disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: 500
Clinical Identifier: DRI10734
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Sanofi-Aventis, US

Contact Information:
Sheela Chandrashekar
Phone: 617-302-6388
Email: study@thealzcenter.org

Back to Top

Location: Call for details

Trial Title and Description: Open-Label Extension Assessing Long Term Safety of Rosiglitazone In Subjects with Mild To Moderate Alzheimer's Disease-

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: February 2006

Condition: Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase 2
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
877-379-3718

Back to Top

MICHIGAN

Location: Adrian
Bixby Oncology Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Michael Uscio
419-843-6147

Back to Top

Location: Detroit
Henry Ford Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Teresa Kay
313-916-3721

Back to Top

Location: Grand Rapids
Grand Rapids Clinical Oncology Program CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Connie M. Szczepanek
616-391-1230

Back to Top

Location: Grand Rapids
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Herman Sullivan
877-379-3718

Back to Top

Location: Kalamazoo
Bronson Lakeview Psychiatry

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease  

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Gail Massey
269-341-8774
masseyg@bronsonhg.org
For more information, visit www.gapstudy.com

Back to Top

Location: Monroe
Monroe Clinic

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Debbie Osemtoski
734-242-8585

Back to Top

Location: Pontiac
St. Joseph Mercy Oakland

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Liz A. Bowie
248-858-6215

Back to Top

Location: Traverse City
Munson Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Pamela J. Bergman
231-935-6300

Back to Top

Location: Call for details

Trial Title and Description: Open-Label Extension Assessing Long Term Safety of Rosiglitazone In Subjects with Mild To Moderate Alzheimer's Disease-

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: February 2006

Condition: Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase 2
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
877-379-3718

Back to Top

MINNESOTA

Location: St. Paul
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Elizabeth Reeve
877-379-3718

Back to Top

Location: St. Paul
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Elizabeth Reeve
877-379-3718

Back to Top

MISSISSIPPI

Location: Mound Bayou
Delta Health Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Not yet recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu

Back to Top

MISSOURI

Location: Joplin
St. John's Regional Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Rita Glaze
417-625-2949

Back to Top

Location: Springfield
Cancer Research for the Ozarks

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Dean A. Matthews
417-269-4880

Back to Top

Location: Springfield
St. John's Health System

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Gail Black
417-269-6513

Back to Top

Location: St. Louis
St. Louis University

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Susan Brown
314-977-4818
brownsa@slu.edu

Back to Top

Location: Call for details

Trial Title and Description: Effect of Memantine on Functional Communication in Patients with Alzheimer's Disease-

The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2007

Condition: Alzheimer's disease
Age Eligibility: 50 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00469456
Study Phase: Phase 4
Study Type: Interventional

Sponsor: Forest Laboratories

Contact Information:
Forest Professional Affairs
800-678-1605

Back to Top

MONTANA

Location: Billings
Montana Cancer Consortium CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Shirley A. Hall
406-259-2245
mcc@mcn.net

Back to Top

Location: Great Falls
Benefits Health Care

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Laura K. Hodges
406-727-4584

Back to Top

NEBRASKA

Location: Kearney
Good Samaritan Health Systems- Cancer Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Connie S. Wittman
308-865-7564

Back to Top

Location: Lincoln
Cancer Resource Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kay L. Hoff
402-483-2827
khoff@lmef.org

Back to Top

Location: Omaha
University of Nebraska Medical Center

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Barbara Bayer
402-552-6005
blbayer@unmc.edu
For more information, visit www.gapstudy.com

Back to Top

Location: Omaha
Alegent Health Bergan Mercy Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Catherine T. Basham
402-572-3223

Back to Top

Location: Omaha
Alegent Health Immanuel Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Catherine T. Basham
402-572-3223

Back to Top

Location: Omaha
Missouri Valley Cancer Cons CCOP/ Creighton University

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Penny Jo Anzures
402-280-5274
panzures@creighton.edu

Back to Top

NEVADA

Location: Las Vegas
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Michael DePriest
877-379-3718

Back to Top

Location: Reno
Wasoe Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Jeannine Moore
775-982-5050

Back to Top

NEW HAMPSHIRE

Location: Lebanon
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
David Coffey
877-379-3718

Back to Top

NEW JERSEY

Location: East Orange
VAMC New Jersey Health Care System

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Karen Long
973-676-1000

Back to Top

Location: Kenilworth
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Justine Kent
877-379-3718

Back to Top

Location:  Lawrenceville, NJ
AdvanceMed Research

Trial Title and Description:  Progress of Mild Alzheimer’s Disease in Participants on Solanezumab (LY2062430) Versus Placebo (EXPEDITION 3)

To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

Enrollment Status:   Recruiting

Study Dates:   Start: September 2013

Condition:   Alzheimer's Disease
Age Eligibility:   55-90  
Gender Eligibility:   Both  
Enrollment Goal:   2100
Clinical Identifier: NCT01900665
Study Phase:   Phase 3
Study Type:   Interventional

Sponsor:   Eli Lilly and Company

Contact Information:
Mary Jane DiFresca
609-895-0735, ext 137
mdifresca@advancemed.info

For more information, visit http://www.advancemed.info/

Back to Top

Location: Morristown
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stuart Fox
877-379-3718 ext. 33

Back to Top

Location: Phillipsburg
Warren Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Bonnie L. Perrucci
908-859-6700

Back to Top

Location: Piscataway
University of Medicine and Dentistry of New Jersey

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Julie Coleman
732-235-4907
colemanjs@umdnj.edu

Alison Grazioli
732-235-4907
alison.formica@qmail.com

William Reichman

Back to Top

Location: Princeton
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jeffrey Apter
877-379-3718

Back to Top

Location: Red Bank
Riverview Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Roxanna Valasa
732-530-2382

Back to Top

Location: Stratford
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stephen Scheinthal
877-379-3718

Back to Top

Location: Toms River
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Gerald Ferencz
877-379-3718

Back to Top

NEW YORK

Location: Albany
Stratton Veterans Affairs Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Lori Megherian
518-626-6448
lori.megherian@med.va.gov

Back to Top

Location: Albany
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
David Hart
877-379-3718

Back to Top

Location: Albany
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Richard Holub
877-379-3718

Back to Top

Location: Brooklyn
Brighton Beach Brooklyn, NY

Trial Title and Description: Forum Cognitiv/AD Study EVP-6124-024

The primary objectives are to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 (2 or 3 mg daily) compared to placebo for 26 weeks in subjects with mild to moderate dementia due to AD currently receiving stable treatment or previously treated with an AChEI (donepezil, rivastigmine, or galantamine).We will be looking for how this may have an effect on cognitive, functional aspects. Patients will be monitored on possible changes in activities of daily living and possible changes in psychiatric and behavioral symptoms.

Enrollment Status: Recruiting

Study Dates: May 2014 - Jan 2017

Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Male or Female
Enrollment Goal: 790
Clinical Identifier: NCT01969123
Study Phase: Phase 3
Study Type: Interventional

Sponsor: FORUM Pharmaceuticals Inc. formerly known as EnVivo Pharmaceuticals, Inc.

Contact Information:

Cara Coniglio
646-747-4061
cconiglio@spristudy.com

Back to Top

Location: Brooklyn
Brighton Beach Brooklyn, NY

Trial Title and Description: Expedition 3 LZAX

Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo. To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's disease (AD) as compared with placebo in participants with mild AD.

Enrollment Status: Currently enrolling

Study Dates: July 2013 to December 2016

Condition: Mild Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Male or Female
Enrollment Goal: 2100
Clinical Identifier: NCT01900665
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Eli Lilly

Contact Information:

Cara Coniglio
646-747-4061
cconiglio@spristudy.com

Back to Top

Location: Brooklyn
Brighton Beach Brooklyn, NY

Trial Title and Description: Nourish AD

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension.

Enrollment Status: Currently recruiting

Study Dates: November 2012 to January 2015

Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: 66-90
Gender Eligibility: Male or Female
Enrollment Goal: 480
Clinical Identifier: NCT01741194
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Accera, Inc.

Contact Information:

Cara Coniglio
646-747-4061
cconiglio@spristudy.com

Back to Top

Location: Brooklyn
Brighton Beach Brooklyn, NY

Trial Title and Description: TauRx

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's disease..

Enrollment Status: Recruiting

Study Dates: February 2013 to October 2015

Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: Up to 89 years old
Gender Eligibility: Male or Female
Enrollment Goal: 833
Clinical Identifier: NCT01689246
Study Phase: Phase 3
Study Type: Interventional

Sponsor: TauRx Therapeutics Ltd

Contact Information:

Cara Coniglio
646-747-4061
cconiglio@spristudy.com

Back to Top

Location: Brooklyn
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:

Nicholas Vatakis
877-379-3718

Back to Top

Location: Cooperstown
Bassett Research Institute

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Anne-Marie Whitaker
607-547-3399
anne-marie.whitaker@bassett.org

Back to Top

Location: Glens Falls
Glens Falls Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Barbara A. Sponzo
518-926-6700

Back to Top

Location: New York City, Mt. Sinai School of Medi cine

Trial Title and Description:
Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI-2) 

The ADNI-2 study, we hope to determine whether imaging of the brain through MRI, PET and amyloid imaging scans can help predict and monitor the onset and progression of Alzheimer’s disease. In addition to neuroimaging, the study will collect and test blood and cerebral spinal fluid to determine if biomarkers can predict and monitor the disease.

Enrollment Status:   Recruiting

Study Dates:   Start: 2011, Expected Completion: 2017

Condition:   Alzheimer's disease; cognitively normal with a memory concern
Age Eligibility:   55-90  
Gender Eligibility:   Both
Enrollment Goal:   650
Clinical Identifier: NCT01231971
Study Phase:   Phase 3
Study Type:   Observational

Sponsor:   National Institute on Aging (NIA), Alzheimer’s Disease Cooperative Study (ADCS)

Contact Information:  
Cleopatra McGovern
212-241-1514
cleopatra.mcgovern@mssm.edu

Back to Top

Location: New York
Columbia University

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Ruth Tejeda
212-305-7661
rbt41@columbia.edu

Back to Top

Location: New York University Langone Medical Center/School of Medicine
145 E. 32 nd Street –Floor 2 – New York, NY 10016

Trial Title: Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer’s Disease

Description: Resveratrol is derived from plants and is found in highest levels in red wine and the skin of red grapes. A recent study reported that monthly and weekly consumption of red wine is associated with a lower risk of dementia. There is compelling evidence that caloric restriction can improve overall health by activating a class of enzymes known as Sirtuins. Resveratrol is a substance found in some plants that directly activates sirtuins, mimicking the effects of caloric restriction and may affect regulatory pathways of diseases of aging, including Alzheimer's disease (AD).

In this study, people with AD will be given either Resveratrol or placebo for 12 months to determine whether daily resveratrol therapy is beneficial in delaying or altering the deterioration of memory and daily functioning. Subjects age 50 and above with a diagnosis of probable AD may qualify for participation in this study. A small group of 15 participants will be asked to take part in a more detailed 24-hour Pharmacokinetic (PK) sub-study that will measure resveratrol levels over a 24 hour period.

Enrollment Status: Recruiting
Study Dates: Study begins June 2012
Expected Completion: December 2013
Condition: Alzheimer’s disease
Age Eligibility: 50 years and above
Gender Eligibility: M and F
Enrollment Goal: 10
Clinical Identifier: ADC-037-RES; Resveratrol
Clinical Trials.Gov: NCT01504854
Study Phase: II
Study Type: Interventional
Sponsor: Alzheimer’s Disease Cooperative Study/National Institute on Aging

Contact Information:
Dana M. Pogorelec (Study Coordinator) (212)-263-5708 dana.pogorelec@nyumc.org
Giuseppe Agugliaro (Assistant Coordinator) (212)-263-5845 giuseppe.agugliaro@nyumc.org

Back to Top

Location: New York University Langone Medical Center/School of Medicine
145 E. 32 nd Street –Floor 2 – New York, NY 10016

Trial Title: Alzheimer’s Disease Neuroimaging Initiative-2

Description: The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Enrollment Status: Recruiting
Study Dates: June 2012
Expected Completion: January 2016
Condition: Mild Cognitive Impairment; Alzheimer’s Disease (also recruiting cognitively normal subjects)
Age Eligibility: 55-90
Gender Eligibility: M and F
Enrollment Goal: 5
Clinical Identifier: ADNI2 (ADC-039)
Clinical Trials.Gov: NCT01231971
Study Phase: NA
Study Type: Observational
Sponsor: Alzheimer’s Disease Cooperative Study/National Institute on Aging

Contact Information:
Dana M. Pogorelec (Study Coordinator) (212)-263-5708 dana.pogorelec@nyumc.org
Giuseppe Agugliaro (Assistant Coordinator) (212)-263-5845 giuseppe.agugliaro@nyumc.org

Back to Top

Location: New York University Langone Medical Center/School of Medicine
145 E. 32 nd Street –Floor 2 – New York, NY 10016

Trial Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Trial Of Bapineuzumab In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers

Description: This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

Enrollment Status: Recruiting
Study Dates: July 2012
Expected Completion: June 2014
Condition: Alzheimer’s Disease
Age Eligibility: 50-88
Gender Eligibility: M and F
Enrollment Goal: 10
Clinical Identifier: Bapineuzumab
Clinical Trials.Gov: NCT00667810
Study Phase: III
Study Type: Interventional
Sponsor: Pfizer

Contact Information:
Dana M. Pogorelec (Study Coordinator) (212)-263-5708 dana.pogorelec@nyumc.org
Giuseppe Agugliaro (Assistant Coordinator) (212)-263-5845 giuseppe.agugliaro@nyumc.org

Back to Top

Location: New York University Langone Medical Center/School of Medicine
145 E. 32 nd Street –Floor 2 – New York, NY 10016

Trial Title: Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Description: The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027 on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and computerized cognitive tests in mild Alzheimer's disease (AD) subjects, following 9 weekly intravenous (IV) infusions of BMS-241027

Enrollment Status: Recruiting (Pending IRB and Sponsor Approval of Site)
Study Dates: Fall 2012
Expected Completion: December 2013
Condition: Alzheimer’s Disease
Age Eligibility: 50-90
Gender Eligibility: M and F
Enrollment Goal: 5
Clinical Identifier: BMS241027
Clinical Trials.Gov: NCT01492374
Study Phase: Ib
Study Type: Interventional
Sponsor: Bristol-Myers Squibb

Contact Information:
Dana M. Pogorelec (Study Coordinator) (212)-263-5708 dana.pogorelec@nyumc.org
Giuseppe Agugliaro (Assistant Coordinator) (212)-263-5845 giuseppe.agugliaro@nyumc.org

Back to Top

Location: New York University Langone Medical Center/School of Medicine
145 E. 32 nd Street –Floor 2 – New York, NY 10016

Trial Title: A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease ( MK-8931-010 AM1 [P07820 AM1])

Description: This study will assess the safety and pharmacodynamics of three different doses of MK-8931, a ß-secretase inhibitor, in participants with mild to moderate Alzheimer's Disease (AD).

Enrollment Status: (Pending Sponsor and IRB)
Study Dates: ---
Expected Completion: ---
Condition: Alzheimer’s Disease
Age Eligibility: 50-85
Gender Eligibility: M and F
Enrollment Goal: 5
Clinical Identifier: MK8931
Clinical Trials.Gov: NCT01496170
Study Phase: I
Study Type: Interventional
Sponsor: Merck

Contact Information:
Dana M. Pogorelec (Study Coordinator) (212)-263-5708 dana.pogorelec@nyumc.org
Giuseppe Agugliaro (Assistant Coordinator) (212)-263-5845 giuseppe.agugliaro@nyumc.org

Back to Top

Location: New York University Langone Medical Center/School of Medicine
145 E. 32 nd Street –Floor 2 – New York, NY 10016

Trial Title: TMS Stimulation and Cognitive Training in Alzheimer Patients

Description: The aim of this study is to examine if combined treatment with TMS and cognitive training (CoTra) for several weeks can produce a sustained improvement in cognitive and behavioral symptomatology of mild to moderate Alzheimer's disease (AD) patients.

Enrollment Status: (Pending Sponsor and IRB)
Study Dates: Fall 2012
Expected Completion: ---
Condition: Alzheimer’s Disease
Age Eligibility: 55-85
Gender Eligibility: M and F
Enrollment Goal: 5
Clinical Identifier: Clinical Trials.Gov: : NCT01168245
Study Phase: I
Study Type: Interventional
Sponsor: Neuronix

Contact Information:
Dana M. Pogorelec (Study Coordinator) (212)-263-5708 dana.pogorelec@nyumc.org
Giuseppe Agugliaro (Assistant Coordinator) (212)-263-5845 giuseppe.agugliaro@nyumc.org

Back to Top

Location: New York
The Weill Cornell Memory Disorders Program (Cornell University)

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Kavita Shah
212-746-6581
kbs2001@med.cornell.edu
For more information, visit www.gapstudy.com

Back to Top

Location: New York
Mount Sinai School of Medical School

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
George Marzloff
212-241-1514
george.marzloff@mssm.edu
For more information, visit www.gapstudy.com

Back to Top

Location: New York
New York University Medical Center

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Erica Epstein
212-263-5708
erica.maya@med.nyu.edu
For more information, visit www.gapstudy.com

Back to Top

Location: New York
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Ram Shrivastava
877-379-3718

Back to Top

Location: New York
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Marcin Sadowski
877-379-3718

Back to Top

Location: Rochester
University of Rochester Medical Center

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Connie Brand
585-760-6585
connie_brand@urmc.rochester.edu
For more information, visit www.gapstudy.com

Back to Top

Location: Rochester
University of Rochester

Trial Title and Description: Depression in Alzheimer's Disease-

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication Sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

Enrollment Status: Recruiting

Study Dates: Start: July 2004

Condition: Alzheimer's disease, Depression
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2, 3
Study Type: Interventional

Sponsor: National Institute of Mental Health (NIMH)

Contact Information:
Collen McCallum
585-760-6547
Collen_Mccallum@urmc.rochester.edu

Kimberly Martin
585-760-6548
Kimberly_Martin@urmc.rochester.edu

Back to Top

Location: Syracuse
Neurological Care of CNY

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Seema Mirje
315-701-4554
smirje@neurocarecny.com

Smita Kittur

Back to Top

Location: Syracuse
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Smita Kittur
877-379-3718

Back to Top

Location: Call for details

Trial Title and Description: A study of V950 in People with Alzheimer's Disease-

The purpose of this study is to test the safety, tolerability and immune response to an investigational vaccine, V950.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00464334
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Merck

Contact Information:
Trial Manager
888-577-8839

Back to Top

NORTH CAROLINA

Location: Durham
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
James Burke
877-379-3718

Back to Top

Location: Raleigh
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Michael Brown
877-379-3718

Back to Top

Location: Call for details

Trial Title and Description: Comparison of 23 mg Donepezil Sustained Release (SR) to 10 MG Donepezil Immediate Release (IR) in patients-

The study consists of a double-blind, double-dummy, parallel-group comparison of 23 mg donepezil sustained release to the currently marketed formulation, 10 mg donepezil immediate release, in patients with moderate to severe Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2007

Condition: Alzheimer's disease
Age Eligibility: 45-90
Gender Eligibility: Both
Enrollment Goal: 1,600
Clinical Identifier: NCT00478205
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Eisai Medical Research Inc.

Contact Information:
Eisai Medical Services
1-888-422-4743

Back to Top

Location: Call for details

Trial Title and Description: Open-Label Extension Assessing Long Term Safety of Rosiglitazone In Subjects with Mild To Moderate Alzheimer's Disease-

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: February 2006

Condition: Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase 2
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
877-379-3718

Back to Top

OHIO

Location: Beachwood
University Hospitals Case Medical Center

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Suee Foxhall
216-983-0796
suzanne.foxhall@uhhospitals.org

Back to Top

Location: Centerville
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Meenakshi Patel
877-379-3718

Back to Top

Location: Cincinnati
Good Samaritan Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Elyce P. Turba
513-872-2293

Back to Top

Location: Cleveland
Case Western Reserve University

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Elaine Ziol
216-844-6328
elaine.ziol@case.edu

Nicole Trites Gunderson
216-844-6419
nicole.gunderson@case.edu

Alexander Auchus

Back to Top

Location: Cleveland
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Alan Lerner
877-379-3718

Robert Palmer
877-379-3718

Back to Top

Location: Columbus
Columbus CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Deborah A. Halk
614-443-5243

Back to Top

Location: Fremont
Fremont Memorial Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu

Back to Top

Location: Maumee
NW Ohio Oncology Center/ St. Luke's Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Brenda Buczek
419-891-5600

Back to Top

Location: Maumee
NW Ohio Oncology Center/ St. Luke's Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Brenda Buczek
419-891-5600

Back to Top

Location: Oregon
St.Charles Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Karen Schultz
419-696-7465

Back to Top

Location: Toledo
St. Vincent Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Jane Ringlein
419-251-4239

Back to Top

Location: Toledo
Toledo Clinic Inc.

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Michael W. Uscio
419-843-6147

Back to Top

Location: Toledo
Toledo Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Maureen Williams
419-479-8885

Back to Top

Location: Toledo
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Cletus Iwuagwu
877-379-3718

Back to Top

Location: Toledo
Toledo CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Diana J. Frie
419-843-6147

Back to Top

OKLAHOMA

Location: Muskogee
Muskogee Regional Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Rebecca A. Maycher
918-684-2387
maychere@muskogeehealth.com

Back to Top

Location: Oklahoma City
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Kerry Cranmer
877-379-3718

Jorge Pahl
877-379-3718

Surinder Randhawa
877-379-3718

Back to Top

Location: Tulsa
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Ralph Richter
877-379-3718

Back to Top

OREGON

Location: Portland
Oregon Health and Science University

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Lisa Loree
503-494-7615
loree@ohsu.edu
For more information, visit www.gapstudy.com

Back to Top

Location: Portland
Oregon Health Sciences University

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Samantha Raphael
503-494-9399
raphaels@ohsu.edu

Joyce Lear
503-494-7615
learj@ohsu.edu

Joseph Quinn

Back to Top

Location: Portland
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Joseph Quinn
877-379-3718

Back to Top

Location: Call for details

Trial Title and Description: BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories-

The purpose of this study is to test the effect of ibuprofen on the levels of a number of different proteins (called biomarkers) in cerebrospinal fluid, blood, and urine to see whether ibuprofen can influence certain biomarkers associated with the progression of Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: October 2005 November 2007

Condition: Alzheimer's disease
Age Eligibility: 70 and above
Gender Eligibility: Both
Enrollment Goal: 40
Clinical Identifier: NCT00239746
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Dana Waichunas
503-494-9399
waichuna@ohsu.edu

Back to Top


For more information, connect with the Alzheimer’s Foundation of America’s licensed social workers. Click here or call 866.232.8484. Real People. Real Care.